What Cheplapharm Arzneimittel does

Cheplapharm Arzneimittel GmbH is a German specialty pharmaceutical company founded in 1998 and headquartered in Greifswald, Germany. The company's core business is acquiring established branded medicines from research-based pharmaceutical companies (Big Pharma) that wish to divest non-core assets and refocus on innovation, and then assuming global responsibility for the continued manufacturing, regulatory compliance, distribution, and marketing of those products. Cheplapharm markets a diversified portfolio of approximately 150 branded pharmaceutical products across more than 145 countries, with roughly one third of the portfolio listed on the WHO Essential Medicines List, including treatments for rare diseases. The company is privately held, family-controlled, and employs approximately 800 people from over 40 nationalities, with offices in Germany (Greifswald, Berlin), Switzerland (Basel, Binningen), France (Levallois-Perret), and Russia (Moscow).

The company operates an asset-light business model: production and packaging are outsourced to a network of over 130 contract manufacturing organizations (CMOs) and suppliers, while commercial activity is executed through regional distribution partners organized into two Business Units (APAC & MEA, Europe & Americas) and direct enterprise sales teams targeting research-based pharma for new acquisition transactions. Revenue is generated from sales of the acquired branded product portfolio on a B2B contract pricing basis with multi-year distributor agreements; no public list prices are disclosed. Underlying technology infrastructure includes SAP S/4HANA as the core ERP, SAP IBP for integrated business planning, CARA eQMS for quality management, TIBCO and Power BI for analytics, and the TraceLink MINT platform (implementation launched 2026) for global supply chain digitalization.

In FY2025 the company reported revenue of €1,658.4 million, up 8.1% year-over-year, and EBITDA of €642.8 million, equating to an industry-leading 38.8% margin. In October 2022, Cheplapharm secured €550 million in growth capital from Atlantic Park and GIC via a subordinated convertible instrument, and in 2026 the company reorganized its Management Board for the next growth phase, appointing Martin Krämer as CFO and transitioning Dr. Keyarasch Parssanedjad into a new Chief Business & Strategy Officer role focused on strategic transactions and Big Pharma partnerships. The company has been rated in the top 6% of the pharmaceuticals sector by Sustainalytics (ESG risk score 21.5) and in the top 23% globally by EcoVadis.

Name

Cheplapharm Arzneimittel

Legal name

CHEPLAPHARM Arzneimittel GmbH

Website

https://cheplapharm.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Cheplapharm Arzneimittel is a German specialty pharmaceutical company that acquires established branded medicines from Big Pharma and distributes a diversified ~150-product portfolio across 145+ countries through an asset-light network of 130+ CMOs and regional partners.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industry

Specialty Pharmaceutical Distributors (HLAIAJAB)

Keywords

• Specialty pharmaceutical products
• Branded medicine acquisition
• Essential medicines supply
• Contract manufacturing network
• Pharmaceutical distribution services

Headquarters

HQ city

Greifswald

HQ country

Germany

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: CHEPLAPHARM generates revenue by acquiring established branded medicines from research-based pharmaceutical companies and selling them globally. The company markets a diversified portfolio of around 150 products across more than 145 countries. Revenue grew 8.1% to €1,658.4 million in FY2025. EBITDA margin of 38.8% demonstrates high profitability.
2. Product Acquisition & Licensing: Core business model involves acquiring original pharmaceutical preparations from innovative pharma companies. These transactions convert to equity via subordinated convertible instruments. The company acts as a sustainable platform enabling Big Pharma to focus on innovation while CHEPLAPHARM ensures continued availability of established brands.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

CHEPLAPHARM acquires long-established branded pharmaceutical products from research-based pharmaceutical companies and assumes responsibility for their continued global supply, marketing, and availability. The company markets a diversified portfolio of approximately 150 products across more than 145 countries, supported by an asset-light network of 130+ contract manufacturing organizations and suppliers. Roughly one third of its products are on the WHO Essential Medicines List, and the platform enables Big Pharma partners to divest established brands and refocus on R&D and innovation.

Product overview

CHEPLAPHARM Arzneimittel GmbH operates as a specialty pharmaceutical company offering a unified platform for the acquisition, continued development, and global distribution of long-established branded medicines originally developed by research-based pharmaceutical companies. The core offering is the CHEPLAPHARM Specialty Pharma Platform, which encompasses approximately 150 branded pharmaceutical products across multiple therapeutic areas. These products are marketed in over 145 countries worldwide, with roughly one-third appearing on the WHO Essential Medicines List. The company works with a network of over 130 contract manufacturing organizations (CMOs) and suppliers to maintain product availability. CHEPLAPHARM's model allows innovation-driven pharma partners to divest established products while CHEPLAPHARM ensures their continued availability and supply globally.

Differentiator

Problem solved

Functional benefit

Products and services

• CHEPLAPHARM Specialty Pharma Platform A sustainable platform for the acquisition, continued development, and global distribution of long-established branded medicines originally developed by research-based pharmaceutical companies. CHEPLAPHARM assumes global supply, regulatory, and marketing responsibility, enabling innovation-focused pharma partners to concentrate on R&D.
• Pharmaceutical Product Portfolio (~150 branded products) A diversified portfolio of approximately 150 established branded pharmaceutical products spanning multiple therapeutic areas and indications, marketed in more than 145 countries worldwide. About one third of products appear on the WHO Essential Medicines List and include therapies for rare diseases.

Quantifiable outcome

• Revenue growth of 8.1% to €1,658.4 million in FY2025
• +5 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration9 records

AI capability1 record

Feature3 records

Partnerships

Two partnerships are on record, tiered core and minor.

• TraceLinkcoreTechnology or Integration · 14 May 2026CHEPLAPHARM is implementing TraceLink's MINT platform to digitize and automate global supply chain operations. The platform enables real-time standardized data exchange between CHEPLAPHARM's SAP environment and diverse ERP systems of global trading partners, reducing administrative workload and improving transparency. This digitalization initiative will serve as foundation for future agentic AI capabilities in supply chain orchestration.
• WHO (World Health Organization)minorOthersOne third of CHEPLAPHARM's products are on the WHO Essential Medicines List, indicating global recognition of product importance for public health.

Scale indicators11 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• STADA Arzneimittel AG: German-headquartered specialty pharma company with a similar model of acquiring and managing established branded and generic medicines across multiple therapeutic areas, distributing globally through a broad partner network. Closely comparable in geography, business model, and product strategy.
• Aspen Pharmacare Holdings: South African-headquartered specialty pharma that has built a global portfolio of acquired established brands, particularly through deals with Big Pharma. Operates an asset-light commercial model with diversified manufacturing and serves patients across emerging and developed markets — directly comparable in acquisition-based strategy.
• Almirall S.A. European specialty pharma focused on dermatology and other established therapeutic areas, with a portfolio-led model of managing mature branded products across European and global markets. Comparable in scale, therapeutic breadth, and emphasis on established branded medicines.
• Viatris Inc. Global pharma formed from the Mylan/Upjohn combination, with a portfolio heavily weighted toward established off-patent branded and generic medicines distributed worldwide. Closely comparable in the focus on maintaining and commercializing legacy Big Pharma brands across diverse markets.
• Hikma Pharmaceuticals PLC: UK-listed specialty pharma with branded and generic operations across MENA, Europe, and the US, including a sizable injectables and established-brand franchise. Comparable in geographic breadth, mix of branded and generic, and emphasis on specialty therapeutic areas.
• Mallinckrodt plc: Specialty pharma company with a portfolio of established branded and specialty hospital products across immunology, neurology, and other therapeutic areas. Comparable focus on mature, niche-therapeutic branded medicines with global distribution.
• Bausch Health Companies Inc. Specialty pharma with a diversified portfolio of established branded prescription and consumer healthcare products across multiple therapeutic areas. Comparable in scale and portfolio breadth, though currently undergoing balance-sheet restructuring.
• Recordati S.p.A. Italian-headquartered specialty pharma with a portfolio spanning rare diseases, specialty, and established primary care brands, distributed globally. Comparable in the European specialty-pharma strategy of acquiring and growing mature branded franchises.

Broad incumbents

• Perrigo Company plc: Global consumer-focused specialty pharma with established OTC and self-care brands. While broader and more consumer-leaning than Cheplapharm, Perrigo's model of managing mature, established product franchises across multiple regions is structurally analogous.
• Sandoz Group AG: Recently spun off from Novartis as a pure-play generics and biosimilars company with a large global portfolio of established off-patent medicines. A larger, broader incumbent with overlapping capabilities in sustaining and distributing legacy brands across 100+ markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cheplapharm Arzneimittel